Update on Epidemiology and Therapeutics for Non-Hodgkin’s Lymphoma

Vose, Julie M.; Chiu, Brian C.‐H.; Cheson, Bruce D.; Dancey, Janet; Wright, John

doi:10.1182/asheducation-2002.1.241

Cited by 50 publications

(34 citation statements)

References 117 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, conjugation of immunotherapeutic monoclonal antibodies with immunomodulators (such as α-Interferon) is also under clinical trials [145] . Other treatment approaches for NHL, drug regimen, efficacy and results of different clinical trials may be found elsewhere in more details [138,139,144,145] . In addition, novel therapeutic approaches, target pathways and potential small molecule inhibitors for treatment of NHL resistant to conventional treatment have also been reviewed recently [146] .…”

Section: Clinical and Therapeutics For Nhlmentioning

confidence: 99%

“…This therapy is among the best treatment for NHL, as NHL is highly radiosensitive. In this therapy, Iodine-131 (Tositumomab) or the Yttrium-90 (Ibritumomab tiuxetan) is conjugated to antibodies against CD20, increasing the specificity, while diminishing off-target damage [145] . In addition, conjugation of immunotherapeutic monoclonal antibodies with immunomodulators (such as α-Interferon) is also under clinical trials [145] .…”

Section: Clinical and Therapeutics For Nhlmentioning

confidence: 99%

“…In this therapy, Iodine-131 (Tositumomab) or the Yttrium-90 (Ibritumomab tiuxetan) is conjugated to antibodies against CD20, increasing the specificity, while diminishing off-target damage [145] . In addition, conjugation of immunotherapeutic monoclonal antibodies with immunomodulators (such as α-Interferon) is also under clinical trials [145] . Other treatment approaches for NHL, drug regimen, efficacy and results of different clinical trials may be found elsewhere in more details [138,139,144,145] .…”

Section: Clinical and Therapeutics For Nhlmentioning

confidence: 99%

“…Chemotherapy is the most imperative treatment and often includes anti-cancer drug combinations [138,144,145] . Methotrexate, Doxorubicin Hydrochloride, Chlorambucil, Nelarabine, Tositumomab, Bleomycin, Cyclophosphamide, Liposomal Cytarabine, Pralatrexate, Romidepsin, Rituximab, Vinblastine Sulfate, Vorinostat, etc., are some of the drugs used for chemotherapy.…”

Section: Clinical and Therapeutics For Nhlmentioning

confidence: 99%

See 3 more Smart Citations

Hepatitis viruses and non-Hodgkin’s lymphoma: A review

Datta

Chatterjee²,

Policegoudra³

et al. 2012

WJV

View full text Add to dashboard Cite

Non-Hodgkin's lymphoma (NHL) is among the haematological malignancies with high prevalence worldwide, causing estimated 355 900 new cases and 191 400 deaths in 2008. High prevalence of NHL is documented in economically more developed areas while low prevalence is observed in less developed areas of the globe. A wide array of environmental factors have been reported to be either directly involved or in modifying the risk of NHL development. In addition to these factors, a number of infectious agents, chiefly viruses have also been implicated in the development of NHL. This article reviews the available literature to discuss the role of hepatitis viruses in NHL development, possible mechanisms of lymphomagenesis and also identify the areas in which further research is required to better understand this disease. A brief discussion on the clinical aspects such as classification, staging, treatment approaches have also been included in this article.

show abstract

Section: Clinical and Therapeutics For Nhlmentioning

confidence: 99%

Section: Clinical and Therapeutics For Nhlmentioning

confidence: 99%

Section: Clinical and Therapeutics For Nhlmentioning

confidence: 99%

Section: Clinical and Therapeutics For Nhlmentioning

confidence: 99%

See 2 more Smart Citations

Hepatitis viruses and non-Hodgkin’s lymphoma: A review

Datta

Chatterjee²,

Policegoudra³

et al. 2012

WJV

View full text Add to dashboard Cite

show abstract

“…Non-Hodgkin's lymphoma (NHL) is the sixth leading cause of cancer death in the United States and has increased in incidence by >80% since 1973 (1,2). NHL can be divided into at least 29 different subtypes of malignancy of either T-or Blymphocyte origin.…”

mentioning

confidence: 99%

A Novel Methionine Aminopeptidase-2 Inhibitor, PPI-2458, Inhibits Non–Hodgkin's Lymphoma Cell Proliferation In vitro and In vivo

Karp

Clark

Taghizadeh

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Fumagillin and related compounds have potent antiproliferative activity through inhibition of methionine aminopeptidase-2 (MetAP-2). It has recently been reported that MetAP-2 is highly expressed in germinal center B cells and germinal center^derived non^Hodgkin's lymphomas (NHL), suggesting an important role for MetAP-2 in proliferating B cells. Therefore, we determined the importance of MetAP-2 in normal and transformed germinal center B cells by evaluating the effects of MetAP-2 inhibition on the form and function of germinal centers and germinal center^derived NHL cells. Experimental Design: To examine the activity of PPI-2458 on germinal center morphology, spleen sections from cynomolgus monkeys treated with oral PPI-2458 were analyzed. Antiproliferative activity of PPI-2458 was assessed on germinal center^derived NHL lines in culture. A MetAP-2 pharmacodynamic assay was used to determine cellular MetAP-2 inhibition following PPI-2458 treatment. Finally, inhibition of MetAP-2 and proliferation by PPI-2458 was examined in the human SR NHL line in culture and in implanted xenografts. Results: Oral PPI-2458 caused a reduction in germinal center size and number in lymphoid tissues from treated animals. PPI-2458 potently inhibited growth (GI 50 = 0.2-1.9 nmol/L) of several NHL lines in a manner that correlated with MetAP-2 inhibition. Moreover, orally administered PPI-2458 significantly inhibited SR tumor growth, which correlated with inhibition of tumor MetAP-2 (>85% at 100 mg/kg) in mice. Conclusions: These results show the potent antiproliferative activity of PPI-2458 on NHL lines in vitro and oral antitumor activity in vivo and suggest the therapeutic potential of PPI-2458 as a novel agent for treatment of NHL should be evaluated in the clinical setting.Non-Hodgkin's lymphoma (NHL) is the sixth leading cause of cancer death in the United States and has increased in incidence by >80% since 1973 (1, 2). NHL can be divided into at least 29 different subtypes of malignancy of either T-or Blymphocyte origin. The vast majority of NHL malignancies are B cell derived. Moreover, a large number of these B-cell malignancies exhibit phenotypic characteristics consistent with a germinal center origin, the site where B cells undergo proliferation and somatic hypermutation.Germinal center -derived B-cell lymphomas can be divided into at least three groups. Follicular lymphoma is responsible for 22% of all NHLs, and almost always exhibits aberrant expression of the antiapoptotic gene 3,4). Follicular lymphoma typically follows an indolent course but often transforms into the more aggressive diffuse large B-cell lymphoma (DLBCL; ref. 5). Whereas at least half of all DLBCLs express germinal center markers (Bcl-6 + , CD10 + ), the remainder may more closely resemble activated B lymphocytes and potentially deserve a distinct classification (6, 7). Under the current classification, DLBCLs represent 40% of all NHLs (8). A third type of germinal center -derived B-cell neoplasm, Burkitt's lymphoma, is highly aggre...

show abstract

Yttrium‐90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome

Tsimberidou

Murray

O’Brien

et al. 2004

Cancer

View full text Add to dashboard Cite

BACKGROUND90Y ibritumomab tiuxetan is a radioimmunotherapeutic construct that is reported to be an effective treatment for patients with lymphoma. The aim of the current analysis was to evaluate retrospectively the efficacy and safety of 90Y ibritumomab tiuxetan in patients with Richter syndrome (RS).METHODSPatients with histologically proven CD20‐positive RS and < 25% lymphoma and/or chronic lymphocytic leukemia in the bone marrow were treated. Patients received an imaging dose of 111In‐labeled ibritumomab tiuxetan of 1.6 mg (5.0 mCi of 111In) intravenously. One week later, they received 0.3 or 0.4 mCi/kg of 90Y ibritumomab tiuxetan. Rituximab, at a dose of 250 mg/m2 intravenously, was given immediately before ibritumomab tiuxetan on Days 1 and 8.RESULTSSeven patients were treated. Their median age was 56 years (range, 44–70 years). The median time to transformation was 7.9 years (range, 0.7–28.4 years). The median number of previous therapies received was five (range, one to seven previous therapies). The median number of previous therapies received for RS was one (range, none to three previous therapies). Six patients were treated previously with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and cytosine arabinoside. No patient responded to 90Y ibritumomab tiuxetan therapy. All patients developed disease progression. The median time to disease progression was 41 days (range, 39–89 days). Side effects included hematologic toxicity. Grade 3–4 (according to the second version of the National Cancer Institute Common Toxicity Criteria) thrombocytopenia and neutropenia occurred in 5 patients (71%) and 2 patients (29%), respectively. There was one episode of septic shock in a patient with Grade 4 neutropenia.CONCLUSIONS90Y ibritumomab tiuxetan had no significant antitumor activity and hematologic toxicity was severe in these heavily pretreated patients with RS. Cancer 2004. © 2004 American Cancer Society.

show abstract

Update on Epidemiology and Therapeutics for Non-Hodgkin’s Lymphoma

Cited by 50 publications

References 117 publications

Hepatitis viruses and non-Hodgkin’s lymphoma: A review

Hepatitis viruses and non-Hodgkin’s lymphoma: A review

A Novel Methionine Aminopeptidase-2 Inhibitor, PPI-2458, Inhibits Non–Hodgkin's Lymphoma Cell Proliferation In vitro and In vivo

Yttrium‐90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome

Contact Info

Product

Resources

About